Suppr超能文献

肾移植受者多次急性排斥反应发作的临床决定因素

Clinical determinants of multiple acute rejection episodes in kidney transplant recipients.

作者信息

Humar A, Payne W D, Sutherland D E, Matas A J

机构信息

Department of Surgery, University of Minnesota, Minneapolis, USA.

出版信息

Transplantation. 2000 Jun 15;69(11):2357-60. doi: 10.1097/00007890-200006150-00024.

Abstract

BACKGROUND

Recipients with multiple (more than one) acute rejection (AR) episodes have significantly lower graft survival rates than those with no AR or only one treated episode. However, fewer than 50% of recipients treated for one AR episode will have another episode.

METHODS

We studied recipients with at least one AR episode to determine whether any clinical features could identify risk factors for multiple AR.

RESULTS

Between January 1, 1984, and June 30, 1997, a total of 1793 recipients underwent a kidney transplant at our institution. Of these, 354 were treated for one AR episode, 307 for more than one. By multivariate analysis, recipients at highest risk for multiple AR episodes were those with initial delayed or slow graft function (relative risk=1.5, P=0.05), those with initially severe AR (as judged by vascular involvement or steroid resistance), and those with an initial early AR episode (<6 months posttransplant). The remaining variables tested were not significant. Graft survival in recipients with more than one AR episode was significantly lower than in those with only one AR episode. Graft survival at 5 years posttransplant was 52.5% in recipients with more than one AR episode and 85.1% in recipients with one AR episode (P=0.0001). Chronic rejection as a cause of graft loss was significantly more common in recipients with more than one vs. only one AR episode (34.8% vs. 8.9%, P=0.001).

CONCLUSION

Clinical features may be used to identify recipients at higher risk for multiple AR episodes. These recipients can then be targeted with more aggressive or novel immunosuppressive regimens in an attempt to reduce the likelihood of another AR episode.

摘要

背景

经历多次(超过一次)急性排斥反应(AR)的肾移植受者的移植肾存活率显著低于未发生AR或仅接受过一次AR治疗的受者。然而,接受过一次AR治疗的受者中,不到50%会再次发生AR。

方法

我们研究了至少经历过一次AR的受者,以确定是否有任何临床特征可识别发生多次AR的风险因素。

结果

在1984年1月1日至1997年6月30日期间,共有1793名受者在我们机构接受了肾移植。其中,354名受者接受了一次AR治疗,307名受者接受了不止一次AR治疗。多因素分析显示,发生多次AR风险最高的受者是那些移植肾功能最初延迟或恢复缓慢的患者(相对风险=1.5,P=0.05),那些最初发生严重AR的患者(根据血管受累情况或对类固醇耐药性判断),以及那些移植后早期(<6个月)发生首次AR的患者。所测试的其他变量均无统计学意义。发生不止一次AR的受者的移植肾存活率显著低于仅发生一次AR的受者。移植后5年,发生不止一次AR的受者的移植肾存活率为52.5%,而仅发生一次AR的受者为85.1%(P=0.0001)。慢性排斥反应作为移植肾丢失的原因,在发生不止一次AR的受者中比仅发生一次AR的受者更为常见(34.8%对8.9%,P=0.001)。

结论

临床特征可用于识别发生多次AR风险较高的受者。然后可针对这些受者采用更积极或新颖的免疫抑制方案,以试图降低再次发生AR的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验